Geoffrey Krystal

Title: Geoffrey Krystal: Innovator in Cancer Treatment

Introduction

Geoffrey Krystal is a notable inventor based in Richmond, VA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patent work. His dedication to improving therapeutic options for patients has positioned him as a key figure in medical research.

Latest Patents

Geoffrey Krystal holds a patent for a combination therapy that includes glivec (STI571) and a cyclin-dependent kinase inhibitor, particularly flavopiridol, for the treatment of cancer. This invention pertains to a combination for simultaneous, separate, or sequential use, which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. This combination is especially relevant for treating Bcr/Abl leukemia that is resistant to the compound of formula I. Geoffrey Krystal has 1 patent to his name.

Career Highlights

Throughout his career, Geoffrey has worked with esteemed institutions, including Virginia Commonwealth University and the United States Government as represented by the Department of Veterans Affairs. His work has focused on advancing cancer therapies and improving patient outcomes through innovative approaches.

Collaborations

Geoffrey has collaborated with notable colleagues such as Steven Grant and Chunrong Yu. These partnerships have contributed to the development of effective cancer treatment strategies and have enhanced the impact of his research.

Conclusion

Geoffrey Krystal's contributions to cancer treatment through his innovative patent and collaborations highlight his commitment to advancing medical science. His work continues to inspire future research in the field of oncology.